Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Tran

Showing results (151-160 of 181) with videos related to

Pageof 19
Sort By:
JAMA|May 6, 2015
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosisAndrew J Muir, Fred Poordad, Jacob Lalezari, et al.
Journal of Hepatology|July 26, 2011
Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 studyJean-Pierre Zarski, Nathalie Sturm, Jérôme Guechot, et al.
Gastroenterology|October 15, 2014
Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infectionGregory J Dore, Eric Lawitz, Christophe Hézode, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|June 28, 2016
Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantationJérôme Dumortier, Vincent Leroy, Christophe Duvoux, et al.
The Lancet. Infectious Diseases|March 17, 2015
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)Marc Bourlière, Jean-Pierre Bronowicki, Victor de Ledinghen, et al.
Liver Cancer|March 6, 2023
Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 TrialZhenggang Ren, Michel Ducreux, Ghassan K Abou-Alfa, et al.
BMC Infectious Diseases|April 4, 2019
Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohortAnne Laurain, Sophie Metivier, Georges Haour, et al.
Hepatology (Baltimore, Md.)|April 28, 2007
Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitisJean-Baptiste Nousbaum, Jean-François Cadranel, Pierre Nahon, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 13, 2017
Direct-acting antiviral agent-based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT studySébastien Dharancy, Audrey Coilly, Claire Fougerou-Leurent, et al.
Hepatology (Baltimore, Md.)|April 11, 2018
12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver TransplantationPauline Houssel-Debry, Audrey Coilly, Claire Fougerou-Leurent, et al.
Pageof 19

Showing results (151-160 of 181) with videos related to

Sort By:
Pageof 19
JAMA|May 6, 2015
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosisAndrew J Muir, Fred Poordad, Jacob Lalezari, et al.
Journal of Hepatology|July 26, 2011
Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 studyJean-Pierre Zarski, Nathalie Sturm, Jérôme Guechot, et al.
Gastroenterology|October 15, 2014
Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infectionGregory J Dore, Eric Lawitz, Christophe Hézode, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|June 28, 2016
Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantationJérôme Dumortier, Vincent Leroy, Christophe Duvoux, et al.
The Lancet. Infectious Diseases|March 17, 2015
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)Marc Bourlière, Jean-Pierre Bronowicki, Victor de Ledinghen, et al.
Liver Cancer|March 6, 2023
Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 TrialZhenggang Ren, Michel Ducreux, Ghassan K Abou-Alfa, et al.
BMC Infectious Diseases|April 4, 2019
Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohortAnne Laurain, Sophie Metivier, Georges Haour, et al.
Hepatology (Baltimore, Md.)|April 28, 2007
Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitisJean-Baptiste Nousbaum, Jean-François Cadranel, Pierre Nahon, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 13, 2017
Direct-acting antiviral agent-based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT studySébastien Dharancy, Audrey Coilly, Claire Fougerou-Leurent, et al.
Hepatology (Baltimore, Md.)|April 11, 2018
12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver TransplantationPauline Houssel-Debry, Audrey Coilly, Claire Fougerou-Leurent, et al.
Pageof 19